Alzheimer’s Finally Has a Strategy
from David's Gemini Notebook Podcast Collection Hosted by David Weissman
After decades when an Alzheimer’s diagnosis offered sympathy but little strategy, medicine has crossed a historic line: treatments can now slow the disease itself. This episode explains how anti-amyloid therapies such as lecanemab and donanemab differ from older symptom-focused medications—and why success means preserving function longer, not restoring memories already lost. Follow the rapidly changing journey from blood-based early detection to ongoing injections, finite infusion therapy, and new approaches to severe agitation. Along the way, the hosts examine brain swelling and bleeding, APOE-e4 genetic risk, demanding MRI surveillance, and the choices families must weigh when more time comes with serious tradeoffs. The central lesson is unmistakable: timing may now determine whether the treatment window remains open.
Embed this episode
No transcript yet.